Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/20/2025

Inflammatory Bowel Disease Diagnosis

Test Performance Characteristics

  • The American Gastroenterological Association guidelines state that CRP has poor sensitivity (only 49-73%) for detecting endoscopically active IBD, meaning approximately 27-51% of patients with active disease will have a normal CRP 1, 2
  • CRP has a sensitivity of only 0.73 (95% CI, 0.64-0.80) at the 5-6 mg/L threshold, meaning 27% of patients with organic disease causing diarrhea will be missed by a negative test 1, 2, 3
  • The negative likelihood ratio is 0.35 (95% CI, 0.27-0.42), which is insufficient to confidently rule out disease 1, 2
  • The AGA guidelines explicitly state low-quality evidence with serious limitations in study design and inconsistency for using CRP to screen for IBD 4

Superior Alternative: Fecal Calprotectin

  • Fecal calprotectin at 50-60 mg/g cutoff has sensitivity of 0.81-0.88 (95% CI, 0.75-0.90) and specificity of 0.87-0.96, substantially superior to CRP 1, 2, 4
  • The positive likelihood ratio for fecal calprotectin at 24.3-30 mg/g cutoff is 30 (95% CI, 14-67), compared to only 3.4 for CRP 1

Clinical Algorithm for IBD Screening

  • The AGA recommends using CRP only when fecal calprotectin or fecal lactoferrin testing is unavailable or not covered by insurance 4
  • CRP should never be used alone to rule out IBD in patients with chronic diarrhea 4
  • First-line: Order fecal calprotectin with 50 mg/g cutoff for optimal rule-out performance 4
  • If fecal calprotectin is elevated (>50 mg/g) or unavailable, proceed directly to colonoscopy with biopsy 4
  • Do not rely on normal CRP to avoid endoscopic evaluation in patients with clinical suspicion for IBD 1, 2, 4

Critical Pitfalls to Avoid

  • Never withhold colonoscopy based solely on normal CRP in symptomatic patients with clinical features suggesting IBD, as the false-negative rate is unacceptably high 1, 2
  • The AGA explicitly recommends against using CRP to screen for IBD in chronic diarrhea (conditional recommendation, low-quality evidence) 4
  • Normal CRP does not exclude microscopic colitis, which requires colonoscopy with biopsy for diagnosis and has no validated blood biomarkers 5
  • In Crohn's disease patients with known symptomatic remission, normal CRP (<5 mg/L) still has unacceptably high false-negative rates for ruling out endoscopic inflammation, with very low certainty of evidence 6, 7
  • The false-negative rate of 21.4% in symptomatic patients means that more than 1 in 5 patients with endoscopically active disease will be incorrectly classified as being in remission 8

Diagnostic Approaches for Inflammatory Bowel Disease

Biomarker Performance

  • The American Gastroenterological Association (AGA) guidelines state that there is very low certainty of evidence supporting the use of normal CRP to rule out endoscopic inflammation in both intermediate and high probability scenarios, with a recommendation against using CRP alone for this purpose 9, 10
  • Fecal calprotectin at a 50 mg/g cutoff has substantially better test performance than CRP, with 81-88% sensitivity and 87-96% specificity for detecting endoscopic inflammation, although the evidence is rated as low certainty 9
  • In patients with Crohn's disease in symptomatic remission, fecal calprotectin <150 mg/g and normal CRP together can rule out active inflammation, avoiding endoscopic evaluation, based on guidelines from the AGA 11
  • For patients with moderate to severe symptoms, elevated fecal calprotectin or serum CRP suggests endoscopic activity, and colonoscopy with biopsy should be considered, as recommended by the AGA 11
  • CRP elevation correlates better with endoscopic disease activity in Crohn's disease than ulcerative colitis, according to research published in the World Journal of Emergency Surgery, and cited by the AGA 12

Post-Surgical Monitoring

  • In asymptomatic CD patients after surgically induced remission within 12 months who are at low risk or on pharmacologic prophylaxis, fecal calprotectin <50 mg/g (not CRP) should be used to avoid routine endoscopic assessment, as per AGA guidelines 9

REFERENCES